{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:05:47Z","timestamp":1784865947737,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["patient-research.elsevier.com","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.diagmicrobio.2014.03.028","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T17:31:38Z","timestamp":1397323898000},"page":"358-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication"],"prefix":"10.1016","volume":"79","author":[{"given":"Lyudmila","family":"Boyanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Davidkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Gergova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiden","family":"Kandilarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivailo","family":"Evstatiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Panteleeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Mitov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/ajg.2013.48","article-title":"Fosfomycin-containing second-line treatment for Helicobacter pylori infection","volume":"108","author":"Barahona-Garrido","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0010","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/AAC.47.10.3138-3144.2003","article-title":"Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods","volume":"47","author":"Best","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10096-005-1307-9","article-title":"In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole","volume":"24","author":"Blacky","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1099\/jmm.0.009993-0","article-title":"Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria","volume":"58","author":"Boyanova","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0025","series-title":"Helicobacter pylori","isbn-type":"print","first-page":"201","article-title":"H. pylori resistance to antibiotics","author":"Boyanova","year":"2011","ISBN":"https:\/\/id.crossref.org\/isbn\/9781904455844"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2007.11.008","article-title":"Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods","volume":"60","author":"Boyanova","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diagmicrobio.2010.03.010","article-title":"Two-decade trends in primary H. pylori resistance to antibiotics in Bulgaria","volume":"67","author":"Boyanova","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/31.1.65","article-title":"The E test for antimicrobial susceptibility testing of Helicobacter pylori","volume":"31","author":"Cederbrant","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0045","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1099\/jmm.0.011270-0","article-title":"Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK","volume":"58","author":"Chisholm","year":"2009","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0050","first-page":"409","article-title":"Worldwide H. pylori antibiotic resistance: a systematic review","volume":"19","author":"De Francesco","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1128\/AAC.00614-06","article-title":"Quinolone resistance in Helicobacter pylori isolates in Germany","volume":"51","author":"Glocker","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0065","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2014.03.028_bb0070","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1111\/j.1440-1746.2009.06220.x","article-title":"Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori","volume":"25","author":"Hirata","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijantimicag.2006.02.015","article-title":"Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients","volume":"28","author":"Kim","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1523-5378.2011.00856.x","article-title":"Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children","volume":"16","author":"Liu","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0090","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0095","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","article-title":"Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"24","author":"Miehlke","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0105","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10156-012-0425-4","article-title":"The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics","volume":"18","author":"Milani","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1523-5378.2009.00737.x","article-title":"High level of antimicrobial resistance in French Helicobacter pylori isolates","volume":"15","author":"Raymond","year":"2010","journal-title":"Helicobacter"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000191204","article-title":"Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori","volume":"79","author":"Suzuki","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0125","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/JCM.01841-07","article-title":"Molecular characterization of Mycobacterium tuberculosis isolates from different regions of Bulgaria","volume":"46","author":"Valcheva","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2013.08.010","article-title":"Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand","volume":"77","author":"Vilaichone","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2014.03.028_bb0135","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3748\/wjg.v16.i10.1279","article-title":"Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori","volume":"16","author":"Zhang","year":"2010","journal-title":"World J Gastroenterol"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T21:30:17Z","timestamp":1538688617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889314001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0732889314001618"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.03.028","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}